Detalles de la búsqueda
1.
Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
HIV Med;
15(1): 57-62, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23980523
2.
Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
HIV Med;
14(7): 391-400, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23298380
3.
Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
HIV Clin Trials;
14(3): 81-91, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23835510
4.
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
HIV Med;
13(7): 406-15, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22416849
5.
Non-Inferiority of Once-Daily Cobicistat-Boosted Darunavir Versus Ritonavir-Boosted Darunavir in Hiv-1-infected Adult Patients: An Adjusted Comparative Analysis of Pooled Phase 3 Data.
Value Health;
17(7): A664, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27202422
Resultados
1 -
5
de 5
1
Próxima >
>>